非典、中东呼吸综合征和新冠疫情期间抑郁症的患病率：系统评价概述方案

Prevalence of depression during the SARS, MERS, and COVID-19 pandemics: A protocol for overview of systematic reviews.

作者信息

Du Li, Chen Ya-Min, Li Ying, Yuan Wei, Wang Jian-Shu

机构信息

The Third People's Hospital of Lanzhou City.

Evidence-Based Nursing Center, School of Nursing, Lanzhou University.

出版信息

Medicine (Baltimore). 2020 Sep 18;99(38):e22235. doi: 10.1097/MD.0000000000022235.

DOI:10.1097/MD.0000000000022235

PMID:32957366

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7505281/

Abstract

BACKGROUND

The outbreak of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has emerged to be the biggest global health threat worldwide. COVID-19 marks the emergence of the third large-scale epidemic related to the coronavirus, after SARS-CoV in 2002 and Middle-East respiratory syndrome coronavirus (MERSCoV) in 2012. The pandemic has had a harmful effect on the public mental health, especially on depression. Increasing systematic reviews (SRs) of coronavirus were focusing on depression. However, the methodological quality of these SRs is unclear. Therefore, to evaluate and compare the normativity of report of SR, we conducted a comprehensive overview of depression during the SARS, MERS, and COVID-19 pandemics.

METHODS

Two independent reviewers will conduct comprehensively searches in PubMed, EMBASE.com, Web of Science, the Cochrane Library, Chinese biomedical literature database (CBM), Chinese National Knowledge Infrastructure (CNKI), Wan fang Database, Chongqing VIP (CQVIP). Reference lists of articles, gray literature, and conference proceedings will also be searched. We will extract the data and assess the methodological quality using the Assessment of Multiple Systematic Reviews-2 (AMSTAR-2) measurement tool and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. General characteristics of the eligible SRs will be summarized and described. We will provide AMSTAR-2 and PRISMA assessments in tabular form for each review, the total percentage of each item will be calculated. Endnote X8 and EXCEL will be used.

RESULTS

Using the draft search strategy of databases, 8 SRs met the a priori criteria and were included. The overview of SRs will be published in a peer-reviewed journal.

CONCLUSION

Our overview will be a comprehensive synthesis of the existing systemic review on depression with SARS, MERS, and COVID-19.

PROTOCOL REGISTRATION

INPLASY202080003.

摘要

背景

由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染引起的2019年新型冠状病毒病（COVID-19）疫情已成为全球最大的公共卫生威胁。COVID-19是继2002年的SARS-CoV和2012年的中东呼吸综合征冠状病毒（MERS-CoV）之后出现的第三次与冠状病毒相关的大规模疫情。这场大流行对公众心理健康产生了有害影响，尤其是对抑郁症。越来越多关于冠状病毒的系统评价（SRs）聚焦于抑郁症。然而，这些SRs的方法学质量尚不清楚。因此，为了评估和比较SR报告的规范性，我们对SARS、MERS和COVID-19大流行期间的抑郁症进行了全面概述。

方法

两名独立评审员将在PubMed、EMBASE.com、科学网、考克兰图书馆、中国生物医学文献数据库（CBM）、中国知网（CNKI）、万方数据库、重庆维普（CQVIP）中进行全面检索。还将检索文章的参考文献列表、灰色文献和会议论文集。我们将使用多重系统评价评估-2（AMSTAR-2）测量工具和系统评价与Meta分析的首选报告项目（PRISMA）声明提取数据并评估方法学质量。将总结和描述符合条件的SRs的一般特征。我们将以表格形式为每项评价提供AMSTAR-2和PRISMA评估，计算每个项目的总百分比。将使用Endnote X8和EXCEL。